1M6MYTD1Å5ÅMAKS.
Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 153,30 € (-19,27 %). Medianen er 146,51 € (-22,85 %).
| Køb |
8 |
| Behold |
3 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Cidara Therapeutics rises to 52-week high after takeover bid from Merck
Cidara Therapeutics' stock climbed to $220.49, marking a 52-week high, driven by Merck's announcement that it intends to acquire Cidara for $221.50 per share (about $9.2 billion). At the center of the deal is the Phase‑3 drug candidate CD388 for influenza. Cidara recently reported no revenue but holds $476 million in cash; analysts mostly downgraded ratings and set price targets at the takeover offer. Data show very high annual returns (1,141.61%) and metrics suggesting overvaluation (price‑to‑book ratio 16.4). » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2025 | |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | -38,35 mio. | - |
| Nettoresultat | -70,93 mio. | - |
| EBITDA | -70,9 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 4,84 mia. € |
Antal aktier | 25,36 mio. |
Højeste/laveste i 52 uger | 190,82 € - 13,12 € |
| Udbytte | Nej |
Beta | 1,53 |
P/E (PE Ratio) | -34,54 |
PEG (PEG Ratio) | -1,17 |
K/I (PB Ratio) | 8,15 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
| Navn | Cidara Therapeutics Aktie |
| CEO | Jeffrey L. Stein |
| Hjemsted | San Diego,
ca USA |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Medarbejdere | 38 |
